Evidence map›Paper›PMID 40578975›Full record

ArticleIn vivo (Athens, Greece)

PLLA Coating of Lyophilized Human Bone Allograft for Long-term Release of Antibiotics.

Mike Barbeck, Jiawei Zhang, Sanja Stojanovic, Milena Radenkovic, Stevo Najman, Anne Foth, Ole Jung, Florian Beuer, Xin Xiong

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Study of the release kinetics of dalbavancin from bone allografts.Journal of materials science. Materials in medicine · 2025
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mike BarbeckClinic and Policlinic for Dermatology and Venereology, University Medical Center Rostock, Rostock, Germany; mike.barbeck@med.uni-rostock.de.
Jiawei ZhangNMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany.
Sanja StojanovicDepartment for Cell and Tissue Engineering, Scientific Research Center for Biomedicine, Faculty of Medicine, University of Niš, Niš, Serbia.
Milena RadenkovicDepartment for Cell and Tissue Engineering, Scientific Research Center for Biomedicine, Faculty of Medicine, University of Niš, Niš, Serbia.
Stevo NajmanDepartment for Cell and Tissue Engineering, Scientific Research Center for Biomedicine, Faculty of Medicine, University of Niš, Niš, Serbia.
Anne FothClinic and Policlinic for Dermatology and Venereology, University Medical Center Rostock, Rostock, Germany.
Ole JungClinic and Policlinic for Dermatology and Venereology, University Medical Center Rostock, Rostock, Germany.
Florian BeuerDepartment of Prosthodontics, Geriatric Dentistry and Craniomandibular Disorders, Charité Universitätsmedizin Berlin, Corporate Member of Freie Universitat Berlin and Humboldt Universität zu Berlin, Berlin, Germany.
Xin XiongNMI Natural and Medical Sciences Institute at the University of Tübingen, Reutlingen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimMineralized allogeneic bone substitutes are ideal biomaterials for bone regeneration in surgeries. Moreover, they are also suitable for releasing antibiotics, delivering initial concentrations many times higher than the minimal inhibitory concentration for relevant bacterial strains, without delaying bone formation. In the present study, the potential of sustained-release long-term antibiotic delivery using allografts was investigated. A broad spectrum of antibiotics, including gentamicin, vancomycin, rifampicin, and clindamycin, was incorporated into the bone blocks using a poly-L-lactic acid (PLLA) polymer coating. MATERIALS AND

methodsAn

resultsThe variant loaded with both vancomycin and rifampicin demonstrated the highest activity against methicillin-sensitive

conclusionBased on these results, future optimization can focus on selecting more efficient release of antibiotics and increasing the encapsulated concentration to sustain antibiotic release over 4 months, thereby improving the bacteriostatic effect

Indexed as

Anti-Bacterial AgentsBone TransplantationCoated Materials, BiocompatiblePolyestersAllograftsAnimalsBone RegenerationBone SubstitutesDelayed-Action PreparationsDrug LiberationFreeze DryingHumansRabbitsRifampinStaphylococcus aureusStaphylococcus epidermidisAnti-Bacterial AgentsBone SubstitutesCoated Materials, BiocompatibleDelayed-Action PreparationsPolyesterspoly(lactide)RifampinVancomycinallograftantibiotic susceptibilityBiocompatibilitybone graft infectionbone regenerationdrug deliverylocal antibiotic deliveryMIC90rabbit tibia

Identifiers

PMID40578975
PMCPMC12223631

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.